DRAFT DOCUMENT FINAL COPY TO REFLECT CONFIRMED. Embed Innovations to Transform Your R&D Procurement Model and. Drive Scientific Activities Efficiency

Transcription

1 Embed Innovations to Transform Your R&D Procurement Model and Drive Scientific Activities Efficiency April 30 May 1, 2018 Boston, US This conference exceeded all of my expectations. The topics, speakers and suppliers were very relevant to my interest. I was able to walk away with many ideas and contacts to benchmark with. I look forward to attending this conference again! GSK, 2017 Attendee Building on the successful conversation in 2017, we are working with the community to prepare for the return of 2 nd annual summit. As the only procurement conference dedicated to serve the R&D sector, we aim to help address the unique challenges and rapidly transforming practice. The 2018 agenda will take a closer look to how sourcing and procurement experts can help accelerate scientific activities during early discovery and pre-clinical phases, what emerging partnership model can be adopted to mitigate risks and reduce exposure, and assess AI and innovative technologies to better manage tail spend and supplier relationships. Join this 2-day highly interactive meeting to share your experience and together explore best practice to maximize value and efficiency to your internal and external stakeholders! Confirmed Speakers: Eric Shobe, Global Director of R&D Procurement, Pfizer Sean Cumbie, Head of Procurement, Global Biotech, AstraZeneca Rinaldo Dorman, Clinical & Medical Category Lead, R&D Procurement, Shire Juan Lepe, Director of Procurement R&D &Technology Category Lead, Alnylam Pharmaceuticals Umar Salahuddin, Director, R&D Sourcing, Biogen Senior Representative, Science Exchange Senior Representative, Thermo Fisher Joseph Richardson, Managing Director & CEO, Professional Purchasing Partners Speakers to be Invited: Moushmi Culver, Associate VP, Global Lead for R&D Sourcing & Procurement, Merck Brian Howell, VP, Global Head of Procurement, R&D, Novartis Business Services Brian Whitlock, VP, Head of Global Procurement R&D, Bristol-Myers Squibb Dennix Truax, Senior Director, Global R&D, Eli Lilly Roberto Vaccaro, Director, R&D Strategic Sourcing, Amgen Lead Partner Expertise Partner

2 Conference Day 1 Monday, April Coffee & Registration Chair s Opening Remarks R&D Procurement Evolution Opening Address: The Ultimate Objective of R&D Procurement Delivering Value and Speed Value, time and quality how should the triangle look like for R&D procurement? The complexity and distinct challenges for R&D procurement, should we still live and breathe through the corporate handbook? What s operational excellence in R&D procurement? Early engagement with your internal and external stakeholders with clearly defined roles Defining parameters for constant review and measurements Eric Shobe, Global Director of R&D Procurement, Pfizer Be Prepared Setting Up Your R&D Procurement Function when Your Organization Transitions from SME to Large Pharma? How should R&D procurement align with business expansion? What are the key toolbox you need? Challenges and lessons learned Strategic Sourcing vs. Strategic Category Management What s the Trend? The shift of focus from sourcing to category management Transitioning from transactional to strategic operations and management of category How can category ownership and management maximize value to drug development and overall R&D programs? Debate: What Innovations Do R&D Procurement Business Model Need You can ask the speakers and wider group on their vision for the future and build a clear idea of how you need to adapt your R&D Procurement Function and get ready for the transformation! Speed Networking & Morning Coffee Rebuild Your Sourcing & Procurement Strategy EDC Case Study Driving value in the form of operational efficiencies Using this to improve partnerships Rinaldo Dorman, Clinical & Medical Category Lead, R&D Procurement, Shire Insource or Outsource? That s Your Question Building a framework to weigh your options Cost/benefit analysis Cultural fit is this an consideration? Lunch & Networking Break Strengthening Your Rapport with Your Supplier SRM and Diversity The talking point SRM and supplier diversity, what does it mean for the R&D sector? Challenges with a global footprint and silo therapeutic portfolio operations Emerging reward/partnership model with your CDROs

3 15.00 Scientific Procurement and Supplier Relationship How to Drive Value? A Story from CRO Senior Representative, Thermo Fisher Reflections & Actions: Based on the sessions this morning, audience will have the opportunity to reflect and discuss on actionable points in a round-table format. Delegates will be able to choose one of the following track to exchange ideas. The goal is to share one key takeaway at the end of the discussion. 1. How should the future R&D Procurement organizational chart look like? 2. Supplier diversity what s the best practice? 3. How should you manage your suppliers? Explore new partnership model from early discovery through clinical trial Ph Afternoon Tea & Networking Break Shopping like Amazon: How Science Exchange Platform Can Enhance R&D Productivity Senior Representative, Science Exchange The Big Dollar Sign: Manage Your Tail Spend It s all about incremental savings turn your tail spend into operational advantage Gaining visibility of your in- and out-goings: increase spend under management From data to actions: identify strategies to tackle spend at a category or supplier level From actions to strategy: re-define your category and sourcing strategy What Did You Sign? Contract Lifecycle Management The longevity of R&D contracts: how often do you review and revise? The foundation of a positive relationship exploring novel partnership-reward model How to manage changes as the project progresses? Understanding your risks to avoid pitfalls Chair s Closing Remarks & Close of Day Private Networking Dinner hosted by Science Exchange by invitation only

4 Conference Day 2 Tuesday, May 1, Coffee & Registration Chair s Opening Remarks Early Drug Discovery to Pre-Clinical Sourcing & Procurement Panel Discussion: Understanding Your Internal Customers Needs to Provide Appropriate and Effective Support Led by: Senior Representative, Science Exchange Getting It Right First Time? Early Discovery Sourcing Tactics Is it true? Immature procurement and sourcing techniques in early drug discovery phases Tailoring processes for best practice working groups with R&D teams and the use of supplier aggregator The increasingly complex scientific service requirements how often do these niche vendors are on your corporate list? Flexibility vs. compliance Sean Cumbie, Head of Procurement, Global Biotech, AstraZeneca Scientific Category Management Why It s Important? Pre-clinical category management what does it entail? Translate your vision and strategy from end-to-end category management The benefits of tactical buying and supplier relationship management Morning Coffee & Networking Break Is R&D Procurement a Privilege to Big Pharma? Decrypting the myth of R&D Procurement is a privilege to large organizations The rise of virtual biotechs and virtual R&D operations, the increased need of having a dedicated expert to manage R&D suppliers and activities Focus on opportunities how can you maximize value to your scientific team? Juan Lepe, Director of Procurement R&D &Technology Category Lead, Alnylam Pharmaceuticals Where to Spend and How to Spend? Asset Utilization Lab Equipment Management and Capital Efficiency What do you actually own? And where are they? Insights through data visualization with a global perspective Effective asset optimization and drive capital efficiency The transition from CAPEX to OPEX: streamline your asset management and new leasing/ owning model Reflections & Actions: Based on the sessions this morning, audience will have the opportunity to reflect and discuss on actionable points in a round-table format. Delegates will be able to choose one of the following track to exchange ideas. The goal is to share one key takeaway at the end of the discussion. Sourcing and Category Management Challenges and Solutions in 1. Early drug discovery and pre-clinical: raw material supplies, scientific services, toxicology, DKPD 2. Clinical Ph1 3: clinical trial, clinical manufacturing, patient recruitment 3. Consumables: laboratory equipment Lunch & Networking Break

5 14.10 Who to Partner With? Innovation in supplier base? Or should you adhere to preferred vendor list? The need to venture out for niche supplier for competency and capability Continual monitoring and vetting to minimize your risks The importance to define liabilities to mitigate risks The New AI Era: E-Sourcing, Spend Analytics and Forecast Build the right platform to get value from AI in procurement Applications in e-sourcing, spend analytics and forecast Realizing strategic sourcing through artificial intelligence and achieve maximum capital efficiency Grow With Your Partner Develop a Long Lasting Relationship Decision time: should you perform dual-sourcing? And should you switch supplier midway through your R&D program? How to avoid a deadlock: advanced vendor lifecycle management Success case study of a fruitful partnership from early clinical through commercialization Chair s Closing Remarks & Close of Conference

6 Deep Dive A Monday, April 30, 2018 R&D Supplier Diversity and Risk Management This interactive breakfast, deep dive session, provides the audience with an exceptional opportunity of understanding important elements of Supply Base effectivity. The takeaways from this session should provide the attendees with the following insights: How to evaluate certain elements of your Supplier Management Program o Does your supply base effectively support your R&D Programs and Business Objectives? o How diversified is your portfolio, with your top providers? o Do you evaluate their overall offerings, or just selected services? How effective is your supplier diversity program? o What percentage of your spend is represented with W/MOB? o Are the service offerings of your diverse suppliers strategic, or tactical? Risk analysis is necessary to assess the level of risk in your Supply Chain: o How do you evaluate risk? How do you quantify risk? How do you mitigate and manage risk? Key Performance Indicators (KPI s) are necessary tools for evaluating Supplier Performance o How do you establish KPI s with your Suppliers? o How often do you meet with Supplier to review performance? o Are your KPI s measurable, reportable and manageable? o Are Supplier Performances used as tools for contract renegotiation & renewal? At the conclusion of this collaborative session, teams will participate in a group activity, requiring interactive participation and a report-out at the end. Led by: Joseph Richardson, Managing Director & CEO, Professional Purchasing Partners Deep Dive B Tuesday, May 1, 2018 Strategic Sourcing & Category Management for R&D in Pharma Strategic is not only a buzz word. It involves a lot of analysis, understanding of business needs and assessing future growth objectives particularly in sourcing and category management in such uncertain R&D segment, particularly pre-clinical areas. This session will offer participants to learn the best practice of: Review your current sourcing strategy and identify areas of improvements From data to platforms what tools do you need to refine your sourcing and category management analysis? The need for a mid- to long-term plan how to develop a holistic framework and reduce your exposure?